CTI BioPharma Corp - Company Profile
Powered by 
All the data and insights you need on CTI BioPharma Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date CTI BioPharma Corp Strategy Report
- Understand CTI BioPharma Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
CTI BioPharma Corp (CTI BioPharma), a subsidiary of Swedish Orphan Biovitrum AB, is a biopharmaceutical company that acquires, develops and commercializes novel therapies for a range of blood-related cancers. Its lead product, Pacritinib is intended for the treatment of patients with myeloproliferative diseases. Its product pipeline includes PACIFICA for the treatment of myelofibrosis patients with severe thrombocytopenia; PAC203 for the patients with ruxolitinib therapy failure; PRE-VENT for COVID-19; PERSIST 1 for all platelets count and PERSIST 2 for platelets counts less than thousand. The company’s commercialized product, Vonjo is targeted for the treatment of adult patients with myelofibrosis patients with severe thrombocytopenia. The company relies on third parties for manufacturing and marketing its products. CTI BioPharma is headquartered in Seattle, Washington, the US.
Headquarters
United States of America
Address
3101 Western Ave Ste 800, Seattle, Washington, 98121-3017
Website
www.ctibiopharma.com
Telephone
1 206 2827100
No of Employees
128
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$53.9M
CTI BioPharma Corp premium industry data and analytics
Products and Services
| Products |
|---|
| Product Pipeline:- |
| Pacritinib |
| PERSIST-1: Myelofibrosis – Phase 3 complete |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Acquisitions/Mergers/Takeovers | In June, the company, was acquired by Swedish Orphan Biovitrum for US$1.7 billion. |
| 2022 | Others | In April, the company announced that it's novel inhibitor VONJO, has been included as recommended treatment for Myeloproliferative Neoplasms by NCCN. |
| 2022 | Regulatory Approval | In February, the company has received approval of VONJO (Pacritinib) from the US FDA for the treatment of myelofibrosis cancer. |
Competitor Comparison
| Key Parameters | CTI BioPharma Corp | Johnson & Johnson | Novartis AG | Bristol-Myers Squibb Co | Incyte Corp |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | United States of America | United States of America |
| City | Seattle | New Brunswick | Basel | Princeton | Wilmington |
| State/Province | Washington | New Jersey | - | New Jersey | Delaware |
| No. of Employees | 128 | 131,900 | 76,057 | 34,100 | 2,524 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Laurent Fischer, Ph.D | Chairman | Executive Board | 2017 | 59 |
| Adam R. Craig, M.D., Ph.D. | Director; President; Chief Executive Officer | Executive Board | 2017 | 57 |
| David H. Kirske | Chief Financial Officer; Executive Vice President; Secretary | Senior Management | 2017 | 69 |
| James K. Fong | Chief Commercial Officer; Executive Vice President | Senior Management | 2022 | 61 |
| Jennifer A. Smith | Senior Vice President - Biometrics | Senior Management | 2018 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward